184 related articles for article (PubMed ID: 22074002)
1. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topkan E; Parlak C; Kotek A; Yapar AF; Pehlivan B
BMC Gastroenterol; 2011 Nov; 11():123. PubMed ID: 22074002
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
Parlak C; Topkan E; Onal C; Reyhan M; Selek U
Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
[TBL] [Abstract][Full Text] [Related]
4. Correlation of
Wilson JM; Mukherjee S; Brunner TB; Partridge M; Hawkins MA
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):370-377. PubMed ID: 28190636
[TBL] [Abstract][Full Text] [Related]
5. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
[TBL] [Abstract][Full Text] [Related]
6. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Wilson JM; Mukherjee S; Chu KY; Brunner TB; Partridge M; Hawkins M
Radiat Oncol; 2014 Jun; 9():146. PubMed ID: 24962658
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy.
Topkan E; Parlak C; Yapar AF
Cancer Imaging; 2013 Oct; 13(3):423-8. PubMed ID: 24240137
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy.
Chang JS; Choi SH; Lee Y; Kim KH; Park JY; Song SY; Cho A; Yun M; Lee JD; Seong J
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):126-33. PubMed ID: 25015206
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer.
Moon SY; Joo KR; So YR; Lim JU; Cha JM; Shin HP; Yang YJ
Clin Nucl Med; 2013 Oct; 38(10):778-83. PubMed ID: 24107806
[TBL] [Abstract][Full Text] [Related]
10. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.
Schellenberg D; Quon A; Minn AY; Graves EE; Kunz P; Ford JM; Fisher GA; Goodman KA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1420-5. PubMed ID: 20056345
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy.
Zhang A; Ren S; Yuan Y; Li X; Zhu X; Jiang L; Li D; Zuo C
Medicine (Baltimore); 2019 Mar; 98(13):e15064. PubMed ID: 30921238
[TBL] [Abstract][Full Text] [Related]
12. Impact of omission of elective nodal irradiation on treatment outcomes in locally advanced pancreatic adenocarcinoma patients treated with definitive concurrent chemoradiotherapy.
Topkan E; Parlak C; Yapar F
Pancreatology; 2012; 12(5):434-9. PubMed ID: 23127533
[TBL] [Abstract][Full Text] [Related]
13. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
[TBL] [Abstract][Full Text] [Related]
14. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.
Chen SW; Hsieh TC; Yen KY; Yang SN; Wang YC; Chien CR; Liang JA; Kao CH
Laryngoscope; 2014 Dec; 124(12):2732-8. PubMed ID: 25042474
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
17. Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients.
Incerti E; Vanoli EG; Broggi S; Gumina C; Passoni P; Slim N; Fiorino C; Reni M; Mapelli P; Cattaneo M; Zanon S; Calandrino R; Gianolli L; Di Muzio N; Picchio M
Nucl Med Commun; 2019 Oct; 40(10):1072-1080. PubMed ID: 31365502
[TBL] [Abstract][Full Text] [Related]
18. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
19. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma.
Duimering A; Riauka T; Nijjar Y; Ghosh S; MacEwan R; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Nijjar T; Fairchild A; Mulder K; Doll C; Wong C; Joseph K
Radiother Oncol; 2019 Jul; 136():21-28. PubMed ID: 31015125
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.
Kim JW; Kim HC; Park JW; Park SC; Sohn DK; Choi HS; Kim DY; Chang HJ; Baek JY; Kim SY; Kim SK; Oh JH
Int J Colorectal Dis; 2013 Sep; 28(9):1217-24. PubMed ID: 23404344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
